Table 3.

Results of combined treatment of IFN or PEG-IFN with RBV in dialysis patients

AuthorPatientsDrug DosesSVRDrop-Out Rate
IFN + RBV
    Mousa et al. (73)20IFN-α 3 MU/wk RBV 200 mg 3 times/wk 24 wk (n = 9); 48 wk (n = 11)66% in 24 wk treatment 55% in 48 wk treatment0%
    Tan et al. (74)5IFN-α-2b 3 MU 2 times/wk RBV 200 mg per day Duration N/AN/A40%, all due to anemia
    Bruchfeld et al. (75)6IFN-α 3 MU 2 times/wk for 4 wk RBV 400 mg twice daily for the first 2 wk followed by 400 mg once daily for 28 wk17%0%
PEG-IFN + RBV
    Rendina et al. (76)35PEG-IFN-α-2a 135 μg/wk RBV 200 mg/d for 24 wk (HCV genotype non-1) or 48 wk (genotype 1)97%14%, 1 pt due to anemia
    Deltenre et al. (77)14PEG- IFN-α-2a 180 μg/wk RBV 800 mg/wk (with individual adjustment according to hemoglobin level) for 2 mo63% in 8 patients available for follow-up21%, none due to anemia
    Bruchfeld et al. (78)6PEG- IFN-α-2b 50 μg/wk (n = 4) or PEG- IFN-α-2a 135 μg/wk (n = 2) RBV loading dose of 400 mg/d was given for 1 wk followed by 200 mg/d for 48 wk (HCV genotype 1 and 4) or 24 wk (genotype 2)50%50%, none due to anemia
    van Leusen et al.(79)7PEG-IFN alfa-2a 135 μg weekly RBV 200 mg every other day for 48 wk (HCV genotype 1 and 4) or 24 wk (genotype 2)71%0%
  • SVR, sustained viral response; N/A, not available; IFN, interferon; PEG-IFN, peginterferon; RBV, ribavirin.